Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from PainReform ( (PRFX) ).
PRF Technologies Ltd., formerly known as PainReform, is an Israel-based healthcare company focused on developing technologies and products in the medical and biopharmaceutical space. The company targets global markets through its innovation-driven platform and relies on experienced leadership with deep roots in biotech, medtech, and financial management to support its growth and capital markets presence.
The board of PRF Technologies announced on February 25, 2026, that veteran life-sciences executive and director Efi Cohen-Arazi was appointed interim CEO, replacing interim CEO Ehud Geller, who remains Executive Chairman. The board also permanently confirmed interim finance chief Eyal Broder as CFO and named director Asaf Shavit to the audit and compensation committees, moves that strengthen governance and executive continuity without stemming from any internal disagreements, according to the company.
The most recent analyst rating on (PRFX) stock is a Sell with a $0.64 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Neutral.
The score is weighed down primarily by weak financial performance (minimal revenue, widening losses, and rising cash burn alongside shrinking equity). Technicals also remain bearish with the stock trading below key moving averages, while valuation cannot be meaningfully assessed due to missing P/E and dividend yield data.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PRF Technologies Ltd., formerly known as PainReform, is an Israel-based healthcare company focused on developing technologies and products in the medical and biopharmaceutical space. The company targets global markets through its innovation-driven platform and relies on experienced leadership with deep roots in biotech, medtech, and financial management to support its growth and capital markets presence.
The board of PRF Technologies announced on February 25, 2026, that veteran life-sciences executive and director Efi Cohen-Arazi was appointed interim CEO, replacing interim CEO Ehud Geller, who remains Executive Chairman. The board also permanently confirmed interim finance chief Eyal Broder as CFO and named director Asaf Shavit to the audit and compensation committees, moves that strengthen governance and executive continuity without stemming from any internal disagreements, according to the company.
Average Trading Volume: 550,861
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.29M
See more insights into PRFX stock on TipRanks’ Stock Analysis page.